DailyClout
0
  • Home
  • Billcam
  • Communities
  • Submissions
  • Events
  • Our Story
  • Shop
  • Donate
  • Become a Member!
  • Login/Sign Up
  • Home
  • Billcam
  • Communities
  • Submissions
  • Events
  • Our Story
  • Shop
  • Donate
  • Become a Member!
  • Login/Sign Up
  • All Posts
  • Bulletin Board
  • Opinion
  • Pfizer Analysis
  • Hot Bills
  • Videos
  • Dr. Naomi Wolf’s Outspoken
  • The Mindful Activist
  • Sponsored Content
  • Press Releases
  • Contributors

DailyClout Opinion Pfizer Reports
Opinion

Report 63: In Q3 2022, Pfizer Wrote Off $450 Million of Expired or Expiring COVID-19-Related Inventory.

February 27, 2023 • by David Shaw

Despite generating over $100 billion in revenue in 2022, Pfizer’s stock has dropped precipitously. Pfizer’s revenue was relatively flat, hovering between $41 billion and $51 billion, from 2014 to 2020. Then, its mRNA COVID-19 “vaccine” was awarded Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) on December 11, 2020. On its Q2 2021 earnings teleconference, Pfizer declared its “mRNA strategy” and presented its SARS-CoV-2 mRNA products, COMIRNATY® and Paxlovid®, to shareholders as “franchise” drugs. Pfizer went on to earn over $81 billion in revenue in 2021.

In Q1 2022, Q2 2022, and Q3 2022, Pfizer projected full year 2022 revenue guidance to exceed $102 billion, a company record. However, from Q2 2022 to Q3 2022, Pfizer’s revenue dropped by $5.1 billion, and it fell short of reaching over $102 billion in revenue.

In Pfizer’s 3rd Quarter 2022 10-9 report, there is a $450 million “write off of inventory related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, which was recorded in the second quarter of 2022.”

Moreover, Pfizer announced to shareholders a Global Fund agreement to supply six million Paxlovid® courses at “not-for-profit prices for low- and lower-middle-income countries.”

Please read the one-page report below.

Pfizer Financial Performance microreport
https://dailyclout.io/wp-content/uploads/Pfizer-Financial-Performance-microreport-1.pdf

Pre-Order Your Copy of the Pfizer Reports Book.

Please support DailyClout.

Become a DailyClout Member.

Spread the love
This DailyClout article is the writer’s opinion.
One of our country’s most important freedoms is that of free speech.
Agree with this essay? Disagree? Join the debate by writing to DailyClout HERE.
Spread the love
#Pfizer antiviral Paxlovid comirnaty Covid vaccine covid vaccines earnings financial mrna mrna vaccine mrna vaccines paxlovid pfizer vaccine stock stock market
Previous StoryTake Action For Freedom on March 7th! Floridians for Medical Freedom
Next StoryThe Fall of Big Pharma is on the Horizon at Long Last

Leave your comment Cancel Reply

(will not be shared)

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent Posts

  • Screenshot 2023-05-29 7.43.44 AM
    “Prevent Genocide 2030” With Dr. Rima Laibow Thursday, 1, Jun
  • Dr. Naomi Wolf Uncovers Pfizer’s Depopulation Agenda, as Evidenced by Its Own Documents
    Dr. Naomi Wolf Uncovers Pfizer’s Depopulation Agenda, as Evidenced by Its Own Documents Thursday, 1, Jun
  • breaking the oath
    Film Highlight “Breaking the Oath: Unauthorized” Thursday, 1, Jun
  • Pfizer BioNTech Vaccine
    Report 73: Pfizer Knew by November 2020 That Its mRNA COVID Vaccine Was Neither Safe Nor Effective. Here Is What Pfizer’s Employees and Contractors Knew and When They Knew It. Wednesday, 31, May
  • Copy of Copy of SPIKE (1)
    Dr. McCullough: Which Virus Will Cause the Next Pandemic? Wednesday, 31, May

Blog Archive

Subscribe to Our Newsletter

  • I agree to receive emails and other content from DailyClout. I understand that I may repeal my consent at any time.

  • Home
  • Contact Us
  • BillCam
  • Communities
  • About Us
  • Submissions
  • Advertise with Us
  • Events
View Cart Checkout
Do you really want to logout of DailyClout?
Yes

You are now leaving DailyClout...